Delhi High Court upholds BMS' patent for cancer drug Dasatinib

摘要

The Delhi High Court has upheld the patent of US-based Bristol Myers Squibs (BMS) for Dasatinib, dashing the hopes of a local company to sell a generic version of the cancer drug and providing some relief to multinational drugmakers who are up in arms against India's patent laws.